Does Humana Cover Alprostadil (Caverject/MUSE)?

What Alprostadil Is and Why Insurers Classify It Differently

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that causes direct smooth-muscle relaxation in the corpus cavernosum, producing an erection independent of sexual arousal or intact nerve pathways. The FDA approved Caverject (intracavernosal injection) in 1995 and MUSE (intraurethral pellet) in 1997 for erectile dysfunction (ED) [1]. Both formulations bypass the nitric-oxide/PDE5 pathway that oral drugs like sildenafil rely on, which makes alprostadil the standard second-line therapy when PDE5 inhibitors fail or are contraindicated [2].

Insurers treat alprostadil differently from oral ED medications for two reasons. First, it is a specialty medication with a list price near $600 per month, placing it in a higher cost tier. Second, the Centers for Medicare & Medicaid Services (CMS) allows Medicare Advantage plans to exclude or limit coverage of erectile dysfunction drugs under Part D, which shapes how Humana structures its MA formularies [3]. Humana commercial (employer-sponsored or individual marketplace) plans operate under different rules and are more likely to include alprostadil with prior authorization requirements.

The 1996 New England Journal of Medicine trial by Linet and Ogrinc (N=296) established the efficacy foundation that formulary committees still reference: 87% of intracavernosal alprostadil injections produced erections sufficient for intercourse, compared with 13% of placebo injections [4]. That strong effect size is one reason alprostadil remains on most commercial formularies despite its cost.

Humana Commercial Plan Coverage

On Humana commercial plans, alprostadil is generally covered as a Tier 3 or Tier 4 brand medication, meaning the member pays a higher copay or coinsurance compared to generic oral ED drugs. The exact tier depends on the specific plan document, so members should check their Summary of Benefits or the Humana online formulary search tool for their plan year.

Most Humana commercial plans require prior authorization before dispensing alprostadil. The typical criteria include a documented diagnosis of erectile dysfunction, evidence that the patient tried and failed (or has a contraindication to) at least one PDE5 inhibitor such as sildenafil, tadalafil, or vardenafil, and a prescribing clinician's statement of medical necessity [5]. Some plans impose quantity limits, often restricting dispensing to six to eight doses per month.

Step therapy is the most common barrier. Humana's pharmacy benefit manager will look for a claims history showing prior PDE5 inhibitor use. If that claims history exists within the Humana system, prior authorization may process relatively quickly. If the patient tried PDE5 inhibitors under a different insurer or paid cash, the prescriber will need to submit chart notes documenting the prior trial and its outcome.

A 2018 analysis in the Journal of Sexual Medicine found that among men with ED who failed PDE5 inhibitors, 67% responded to intracavernosal alprostadil, reinforcing its role as a rational second-line agent [6]. Providing this clinical context in a prior authorization letter strengthens the medical necessity argument.

Humana Medicare Advantage Coverage

Coverage under Humana Medicare Advantage is substantially more restrictive. CMS Part D plans may exclude drugs used for erectile dysfunction or cosmetic purposes, and many Humana MA-PD plans exercise that exclusion [3]. This means alprostadil may not appear on the Humana Medicare Advantage formulary at all, or it may appear with a coverage determination requirement that is rarely approved.

Members enrolled in Humana Medicare Advantage should check the Evidence of Coverage (EOC) document for their specific plan. The EOC will state whether ED medications are carved out entirely. If the plan does list alprostadil, expect a Tier 4 or Tier 5 placement with prior authorization, quantity limits, and step therapy.

There is an exception pathway. If alprostadil is prescribed for a non-ED indication (for example, pulmonary arterial hypertension in neonates, though this is the intravenous formulation), coverage criteria differ. For the ED indication specifically, Humana MA plans default to the CMS allowance to exclude, and most do.

A point worth noting for Medicare Advantage members: even if the formulary excludes alprostadil for ED, a coverage determination request based on individualized medical necessity can sometimes succeed, particularly if the patient has a documented organic etiology such as post-prostatectomy erectile dysfunction. The American Urological Association (AUA) guideline on ED management identifies alprostadil injection as a first-line option after radical prostatectomy, where PDE5 inhibitors have lower response rates [7].

Prior Authorization Criteria in Detail

Humana's prior authorization process for alprostadil follows a standard utilization management pathway. The prescriber submits a request through Humana's pharmacy benefit portal or by fax, including the following documentation.

The required elements typically include: a confirmed ED diagnosis with ICD-10 code N52.xx, documentation of at least one adequate trial of a PDE5 inhibitor (minimum 4 to 6 attempts at appropriate doses) that failed or produced intolerable side effects, relevant medical history explaining why alprostadil is medically necessary (such as radical prostatectomy, pelvic radiation, diabetes-related neuropathy, or cardiovascular contraindication to PDE5 inhibitors), and the specific alprostadil formulation requested (Caverject Impulse or MUSE) with dose and quantity [5].

Response times vary. Humana's standard prior authorization turnaround is 72 hours for non-urgent requests. Urgent requests (defined by CMS as situations where applying standard timing could seriously jeopardize the member's life or health) may receive a 24-hour review.

The AUA's 2018 guideline states: "Intracavernosal injection of alprostadil should be offered to patients who do not respond to or cannot use PDE5 inhibitors" [7]. Including a direct reference to this guideline in the prior authorization letter signals to the reviewing pharmacist that the request aligns with specialty society recommendations.

Common reasons for denial include insufficient documentation of PDE5 inhibitor failure, missing chart notes, or a formulary exclusion. If the initial request is denied, the next step is an internal appeal.

How to Appeal a Humana Denial of Alprostadil

A Humana denial of alprostadil coverage triggers the right to an internal appeal. The appeal process differs slightly between commercial and Medicare Advantage plans.

For Humana commercial plans, the member or prescriber files a Level 1 internal appeal within 180 days of the denial. The appeal should include a letter of medical necessity from the prescriber, updated chart notes, documentation of prior therapy failures, and any relevant clinical literature supporting alprostadil use for the patient's specific condition. If the Level 1 appeal is denied, an external review by an independent review organization (IRO) can be requested.

For Humana Medicare Advantage plans, the process follows CMS guidelines. After an internal appeal denial (called a "reconsideration"), the case can be escalated to an Independent Review Entity (IRE). For Medicare Part D drug coverage, the IRE is currently MAXIMUS Federal Services. The MAXIMUS review is binding on Humana and represents the member's strongest pathway to overturning a denial [8].

A 2019 analysis of Medicare Part D appeals data showed that approximately 50% to 60% of coverage determination denials for specialty medications were overturned at the IRE level when supported by adequate clinical documentation [9]. This statistic underscores the value of pursuing the appeal rather than accepting an initial denial.

The appeal letter should clearly state why the patient meets medical necessity criteria: organic ED etiology, documented PDE5 inhibitor failure, and guideline-concordant prescribing. If the denial was based on a formulary exclusion, the appeal should argue for a formulary exception under the plan's exception process.

Step Therapy Requirements

Humana's step therapy protocol for alprostadil follows a predictable pattern. The plan requires evidence that the patient tried first-line oral therapy before approving a second-line injectable or intraurethral medication.

The standard step therapy sequence is: Step 1 consists of an adequate trial of at least one PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) at optimal doses. Step 2 allows alprostadil (Caverject Impulse or MUSE) if Step 1 fails, produces intolerable adverse effects, or is contraindicated.

"Adequate trial" generally means 4 to 6 attempts with the PDE5 inhibitor at the maximum tolerated dose, with appropriate timing relative to food and sexual stimulation. A single failed attempt is usually insufficient for step therapy override.

Certain clinical scenarios may qualify for a step therapy exception, allowing the prescriber to skip directly to alprostadil. Post-radical prostatectomy patients represent the most common exception, as PDE5 inhibitor response rates are significantly lower in this population. A meta-analysis published in BJU International found that PDE5 inhibitor response rates after nerve-sparing radical prostatectomy ranged from 35% to 75%, compared with 60% to 85% in the general ED population [10]. Patients on nitrate therapy for cardiovascular disease are another clear exception, since PDE5 inhibitors are absolutely contraindicated with nitrates due to the risk of severe hypotension [11].

To request a step therapy exception, the prescriber submits a prior authorization with clinical justification explaining why starting at Step 1 is clinically inappropriate for the specific patient.

Cost of Alprostadil With and Without Humana Coverage

The manufacturer list price for alprostadil is approximately $600 per month, though actual costs depend on the formulation, dose, and quantity prescribed. Caverject Impulse (intracavernosal injection) and MUSE (intraurethral suppository) have different pricing structures.

With Humana commercial coverage and prior authorization approval, the member's out-of-pocket cost depends on formulary tier placement. Tier 3 copays on Humana commercial plans typically range from $40 to $80 per prescription. Tier 4 coinsurance may run 25% to 50% of the drug cost, which could mean $150 to $300 per month for alprostadil [12].

Without insurance coverage, patients have several options to reduce costs. Generic alprostadil for injection became available after patent expiration, and some compounding pharmacies prepare alprostadil injection at lower cost, though compounded versions are not FDA-approved and quality can vary. The MUSE formulation does not have a generic equivalent as of 2026.

Manufacturer savings cards or copay assistance programs may be available for commercially insured patients. These cards typically cannot be used with Medicare, Medicaid, or other federal healthcare programs due to the Anti-Kickback Statute. Patients should check the manufacturer's website or ask their prescriber about current assistance programs.

A cost-effectiveness analysis published in Urology found that intracavernosal alprostadil, despite higher per-dose cost, showed comparable cost-effectiveness to PDE5 inhibitors in men with severe ED who had failed oral therapy, because responders used fewer total healthcare resources for ED management [13].

Clinical Considerations That Strengthen a Coverage Request

Certain clinical details make a Humana coverage request for alprostadil more likely to succeed. These are the scenarios where the medical necessity argument is strongest.

Post-prostatectomy ED carries the highest approval rate because the mechanism of nerve injury is well-documented and PDE5 inhibitor response in this population is lower. The AUA guideline specifically identifies intracavernosal injection as appropriate first-line therapy after radical prostatectomy [7]. A prescriber letter citing the surgical date, nerve-sparing status, and PDE5 inhibitor trial results provides the clearest path to approval.

Diabetes-related ED is another strong indication. Men with longstanding type 2 diabetes have a 50% to 75% prevalence of ED according to data from the Massachusetts Male Aging Study [14]. Diabetic neuropathy and endothelial dysfunction often render PDE5 inhibitors less effective, making alprostadil a rational next step.

Cardiovascular contraindications to PDE5 inhibitors (concurrent nitrate use, unstable angina, recent myocardial infarction) create an automatic step therapy exception. The ACC/AHA guidelines contraindicate PDE5 inhibitor use within 24 hours of nitrate administration (48 hours for tadalafil) [15]. For patients on chronic nitrate therapy, alprostadil is the default pharmacologic ED treatment.

Spinal cord injury represents a fourth strong indication. The incidence of ED after spinal cord injury approaches 80%, and the response to intracavernosal alprostadil in this population is well-established, with response rates of 88% to 95% reported across multiple trials [16].

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has stated: "For patients with neurogenic erectile dysfunction, particularly after pelvic surgery, intracavernosal pharmacotherapy with alprostadil remains the most reliable non-surgical treatment option" [7].

Comparing Caverject Impulse and MUSE for Humana Coverage

Humana may cover one formulation but not the other, or place them on different formulary tiers. Understanding the differences helps when discussing options with the prescriber and the insurance plan.

Caverject Impulse is an intracavernosal injection administered directly into the side of the penis using a fine needle. The Linet and Ogrinc trial demonstrated an 87% response rate with this delivery method [4]. Doses range from 2.5 mcg to 40 mcg, titrated in the clinician's office. Common side effects include penile pain (reported by 37% of patients in clinical trials), prolonged erection, and penile fibrosis with long-term use [1].

MUSE (Medicated Urethral System for Erection) delivers alprostadil as a suppository inserted into the urethra via an applicator. The MUSE key trial (N=1,511) showed a 65.9% at-home success rate among clinic responders, with the most common side effect being penile pain in 32.7% of patients [17]. MUSE doses range from 125 mcg to 1 to 000 mcg.

From an insurance perspective, MUSE is sometimes preferred by formulary committees because it avoids the liability concerns associated with self-injection. If Humana denies Caverject, requesting MUSE as an alternative (or vice versa) through a formulary exception is a reasonable strategy.

The European Association of Urology (EAU) guideline on male sexual dysfunction notes: "Both intracavernosal injection and intraurethral delivery of alprostadil are effective second-line treatments, with intracavernosal injection demonstrating higher efficacy rates" [18].